Primary Care - Continuous Glucose Monitoring

Type 2 Diabetes Mellitus Clinical Trial

— PC-COSMO  

Official title:

Continuous Glucose Monitoring in Patients With Diabetes Mellitus Type 2 in Primary Care

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03253237
• Other study ID #: DNOOM1072014
• Status: Recruiting
• Phase: N/A
• First received: August 14, 2017
• Last updated: August 17, 2017
• Start date: August 1, 2017
• Est. completion date: October 7, 2017

Study information

• Verified date: August 2017
• Source: University of Zagreb
• Contact: Valerija Lang, PhD
• Phone: +385915202230
• Email: valerija.bralic.lang[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Introduction and objective: The key to optimal diabetes management is tight glucose control. Hemoglobin A1c is the gold standard to assess glycemic control but in cases of unrecognized hypoglycemia, confusing nighttime events or in cases of large variations in blood glucose, a haemoglobin A1c can not detect specific movement of blood glucose. Continuous glucose monitoring (CGM) provides informations of glucose levels in a real-time format and may be helpful for making the personalized therapy decisions desired in the era of precision medicine. Our aim is to analyse the benefit of tracking patterns of glucose values by using continuous glucose monitoring (CGM) in patients with T2DM in family medicine office.

Description:

STUDY DESIGN: An observational, multicenter, cross-sectional study. A total of 20 GPs from four Croatian regions will recruit up to five subjects of both sexes from August 2017 till the end of September 2017, diagnosed with type 2 diabetes mellitus at least one year prior to study entry, aged ≥40 years, with no insulin in therapy and with clinical suspicion of hypoglycemia or with disproportion in actual glycemia na haemoglobin A1c findings. Sociodemographic, laboratory (HbA1c, fasting and postprandial glucose, total cholesterol, high density cholesterol, low density cholesterol, triglyceride and serum creatinine) and habits data will be collected. SETTING: Totally 100 of patients will be included. At primary care office each patient wear the device (iPro™2 Medtronic) subcutaneously for up to 7-days and return it to the office for download. Patients do not receive glucose alerts and only see the CGM data after it's been analyzed by the healthcare professional. A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: October 7, 2017
• Est. primary completion date: September 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• T2DM diagnosed at least one year prior to study entry

• no insulin in therapy

• patients' ability to understand and answer the questionnaire by themselves

• signed informed consent

Exclusion Criteria:

• known coagulopathy

• oral anticoagulants in therapy

• skin disease that enables continuous glucose monitor device application

• febrile illness

• patient's inability to physically visit a general practitioners office

• patient's inability to answer the questionnaire by themselves

Related Conditions & MeSH terms

• Continuous Glucose Monitoring
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Device:
• continuous glucose monitoring (CGM)
A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.

Locations

Country	Name	City	State
Croatia	Association of teachers in general practice / family medicine	Zagreb

Sponsors (2)

Lead Sponsor	Collaborator
University of Zagreb	Association of teachers in general practice / family medicine

Country where clinical trial is conducted

Croatia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glycemic variability in individuals with type 2 diabetes mellitus in primary care measured by continuous glucose monitor device		7 days